/

Società

Ho

Non verificato

Holoclara

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

3 comunicati stampa

Guarda tutti i comunicati

18/12/2024

Industria

Biotecnologia

Farmaceutica

Salute

Medicina - Varie

Holoclara Selects Eosinophilic Esophagitis as its Lead Indication for HC002, a First-in-Class Worm-Derived Therapy

Fonte

Emittente

1.00

0

18/12/2024

Biotecnologia

Salute

Medicina - Varie

Industria

Holoclara Initiates Phase 1 Clinical Trial Evaluating Worm-Derived Therapeutic HC002 in Healthy Adults

Fonte

Emittente

1.00

0

27/06/2024

Scienza

HIV, AIDS e malattie autoimmuni

Igiene alimentare

Biotecnologia

Salute

Farmaceutica

Sanità

Holoclara Announces $16 Million Series A Financing to Advance a Breakthrough Class of Worm-Derived Therapies for Allergic and Autoimmune Disease

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0